Iqirvo access guide: country options for cross-border named-patient access
Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
About Iqirvo
Iqirvo (elafibranor) is a peroxisome proliferator-activated receptor (PPAR-alpha and PPAR-delta) agonist approved by the US Food and Drug Administration for primary biliary cholangitis (PBC) in adults inadequately responsive to ursodeoxycholic acid (UDCA), in combination with UDCA or as monotherapy when UDCA is not tolerated. The current FDA label is available at accessdata.fda.gov. Iqirvo is marketed by Ipsen. Reserve Meds coordinates US-sourced cross-border access to Iqirvo under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Iqirvo in each jurisdiction Reserve Meds has authored.
Iqirvo country-specific access guides
Reserve Meds has published 5 country-specific access guides for Iqirvo. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.
Bahrain
Read the Bahrain access guide for Iqirvo.
Read the guideBangladesh
Read the Bangladesh access guide for Iqirvo.
Read the guideJordan
Read the Jordan access guide for Iqirvo.
Read the guidePakistan
Read the Pakistan access guide for Iqirvo.
Read the guideQatar
Read the Qatar access guide for Iqirvo.
Read the guideOther countries not yet authored
Reserve Meds has authored country-specific access guides for Iqirvo in the 5 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Iqirvo. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.
Request a Iqirvo access scope for your country
Related Reserve Meds resources
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.
Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
Frequently asked questions
How can I get Iqirvo if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Iqirvo for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Iqirvo through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Iqirvo. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Iqirvo through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Iqirvo to a patient?
Reserve Meds sources Iqirvo from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Iqirvo cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Iqirvo?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.